Biosimilars market to be worth $19.4bn by 2014
The biosimilars sector is predicted to be worth $19.4bn (€13.6bn) by 2014, by which time the US will have overtaken Asia as the dominant market, according to a report.
Archives for September 2, 2009
KV rehiring after FDA accepts work plan
KV Pharmaceutical has begun rehiring employees to produce verification batches of certain products prior to resuming commercial manufacture, which appears to be on schedule after the FDA accepted the work plan.
Cel-Sci hopes “True Cold” gets warm reception in biologics sector
Biotechnology firm Cel-Sci claims the “True Cold” low-temperature fill and finish service at its new manufacturing facility near Baltimore, Maryland is a first for the global contracting sector.
CROs can make “enormous leap” with adaptive operations
An “enormous leap in productivity” can be achieved by applying the principles of adaptive trials to broader operations, such as recruitment, according to a CEO that thinks CROs have to adopt the method.
Controlled-release can deliver for generics firms, says Espicom
Wyeth’s battles to protect the controlled-release (CR) version of its anti-depressant Effexor are a sign of things to come according to a new Espicom report identifying 30 CR drugs likely to face competition.
MDS trying to sell Pharma Services business
Facing “unparalleled” challenges MDS is seeking a buyer for its Pharma Services division, and claims to have begun discussions with two interested parties, to allow it to focus on its Nordion business.
Cali OKs Stemedica to manufacture stem cells for trials
Stemedica Cell Technologies’ new license to make stem cells for trials positions the firm as a “valuable resource for front line researchers,” according to VP of business development Dave McGuigan.